4//SEC Filing
Lavino Francesco Maria 4
Accession 0001104659-20-015173
CIK 0001641640other
Filed
Feb 9, 7:00 PM ET
Accepted
Feb 10, 8:28 PM ET
Size
7.6 KB
Accession
0001104659-20-015173
Insider Transaction Report
Form 4
Lavino Francesco Maria
Chief Commercial Officer
Transactions
- Award
Stock Options
2020-02-06+210,000→ 210,000 totalExercise: $1.35Exp: 2030-02-05→ Ordinary Shares (210,000 underlying) - Award
Ordinary Shares
2020-02-06+105,000→ 180,830 total
Footnotes (3)
- [F1]The reported transaction involved the reporting person's receipt of a grant of 105,000 restricted stock units. The total reported in Column 5 includes the 105,000 newly awarded restricted stock units.
- [F2]The option was granted on February 6, 2020, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right.
- [F3]The option will vest over a four-year period beginning on February 6, 2020. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period.
Documents
Issuer
Nabriva Therapeutics plc
CIK 0001641640
Entity typeother
Related Parties
1- filerCIK 0001711517
Filing Metadata
- Form type
- 4
- Filed
- Feb 9, 7:00 PM ET
- Accepted
- Feb 10, 8:28 PM ET
- Size
- 7.6 KB